Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Hunter syndrome (mucopolysaccharidosis type II) is a rare X-linked lysosomal storage disorder caused by iduronate-2-sulfatase deficiency, leading to glycosaminoglycan accumulation. As per Adjoa Safoa Panyin Quaicoe et al. (2025), its global incidence is approximately 1 in 162,000 live male births. According to Hunter syndrome (MPS II) epidemiology forecast by Expert Market Research, disease burden is expected to remain clinically significant.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Hunter Syndrome (MPS II) – Number of Cases by Year

Read more about this report - Request a Free Sample

Hunter Syndrome (MPS II) Epidemiology Forecast Report Coverage

Expert Market Research's “Hunter syndrome (MPS II) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Hunter syndrome (MPS II). It projects the future incidence and prevalence rates of Hunter syndrome (MPS II) cases across various populations. The study covers age, gender, and type as major determinants of the Hunter syndrome (MPS II) population. The report highlights patterns in the prevalence of Hunter syndrome (MPS II) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Hunter syndrome (MPS II) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Hunter Syndrome (MPS II) Understanding: Disease Overview

Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a rare, progressive lysosomal storage disorder caused by pathogenic variants in the IDS gene, resulting in deficient iduronate-2-sulfatase activity. This enzyme deficiency causes glycosaminoglycans to accumulate in cells and progressively damage multiple organs, including the skeletal system, heart, respiratory tract, and central nervous system. MPS II is inherited in an X-linked manner and primarily affects males, although rare symptomatic females have been reported. Clinically, the disease is broadly categorized into severe, neuronopathic and attenuated, non-neuronopathic forms.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Males with pathogenic IDS variants. MPS II is X-linked and predominantly affects males. Individuals with a family history of MPS II are also important candidates for genetic evaluation

Key Diagnostic Method

Iduronate-2-sulfatase enzyme activity testing and molecular genetic testing. Diagnosis is established through deficient enzyme activity and/or identification of a pathogenic IDS variant

Major Risk Factor

Pathogenic IDS gene variants. Reduced or absent iduronate-2-sulfatase activity causes glycosaminoglycan accumulation and disease manifestations

Major gap in the market

Delayed diagnosis and limited access to specialized diagnosis and treatment. The rarity and multisystem presentation of MPS II can complicate recognition, while treatment access varies across healthcare systems

Hunter Syndrome (MPS II) Epidemiology Perspective

The Hunter syndrome (MPS II) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Hunter syndrome (MPS II) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Hunter syndrome (MPS II) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Mucopolysaccharidosis type II (MPS II) is a rare disorder with epidemiological estimates varying across populations. According to Adjoa Safoa Panyin Quaicoe et al. (2025), global incidence is one in 162,000 live male births.

Gender-Specific Cases of the Disease

MPS II occurs almost exclusively in males because of its X-linked inheritance pattern. According to Barbara K. Burton et al. (2025), female patients represented 1.1% of patients in the Hunter Outcome Survey, highlighting the rarity of affected females.

Age-Specific Cases of the Disease

Disease onset generally occurs during early childhood. According to Adjoa Safoa Panyin Quaicoe et al. (2025), symptoms usually begin at preschool age, while Takeda Pharmaceuticals U.S.A., Inc. reports diagnosis predominantly between 18 and 36 months.

Ethnicity-Wise Cases of the Disease

Epidemiological variation has been reported across ethnic populations. As per Takeda Pharmaceuticals U.S.A., Inc., estimated incidence is higher in certain ethnicities. Krithi Rao et al. (2023) also reported a higher rate among Jews in Israel.

Mortality and Survival Analysis of the Disease

MPS II has a progressive disease course, with the rate of progression varying among affected individuals. According to the National Library of Medicine, the condition is progressively debilitating, while disease progression differs between individuals.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Neuronopathic Form

The neuronopathic form represents the more severe clinical phenotype of Hunter syndrome and is characterized by neurological involvement, developmental impairment, and progressive multisystem disease.

Non-Neuronopathic Form

The non-neuronopathic form represents a less neurologically affected phenotype, with disease burden primarily involving somatic systems such as the skeletal, respiratory, cardiovascular, and gastrointestinal systems.

Hunter Syndrome (MPS II) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Hunter Syndrome (MPS II) Epidemiology

The Hunter syndrome (MPS II) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Qi Kang et al. (2024), the incidence of MPS in the United States was 0.98 per 100,000 live births, with MPS I, II, and III each accounting for 26% of cases. As per Olulade Ayodele et al. (2024), MPS II birth prevalence was approximately one in 73,000 in recent screening studies.

Germany

MPS II epidemiology in Germany follows the broader pattern of this rare X-linked disorder, with affected individuals predominantly being male. The epidemiological profile is also characterized by early childhood symptom onset and variation in disease progression.

France

In France, MPS II represents a rare inherited disorder within the mucopolysaccharidosis spectrum. Its epidemiological profile is characterized predominantly by affected males, with symptoms generally emerging during early childhood.

Italy

Italy reflects the predominantly male epidemiological distribution reported for MPS II. The condition generally becomes apparent during early childhood, while the clinical progression can vary among affected individuals.

Spain

MPS II in Spain follows the broader epidemiological characteristics of this rare X-linked disorder. Affected individuals are predominantly male, and symptoms commonly emerge during the early childhood period.

United Kingdom

According to Krithi Rao et al. (2023), MPS II incidence in the United Kingdom was one in 171,132 live births, equivalent to 0.584 per 100,000 live births. The disease predominantly affects males and generally presents during childhood.

Japan

As per Olulade Ayodele et al. (2024), newborn-screening initiatives estimated MPS II birth prevalence in Japan at approximately one in 15,000, indicating substantial population-level variation compared with estimates from the United States.

India

According to Krithi Rao et al. (2023), MPS II is predominantly observed among males in India. The epidemiological profile is characterized by its rare occurrence, early-life presentation, and occasional reports of affected females.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The Hunter syndrome epidemiology landscape presents opportunities to improve early diagnosis, genetic confirmation, and access to disease-specific treatment across the United States, Europe, Japan, and India. The multisystem nature of MPS II can result in patients being evaluated by multiple specialties before a definitive diagnosis is established. Expanded awareness among pediatricians, geneticists, metabolic specialists, and other relevant clinicians could support earlier referral for enzyme and molecular testing. In India, published clinical cohorts demonstrate an established pool of genetically characterized patients, creating opportunities to strengthen diagnostic infrastructure, genetic counseling, and access to specialized therapies.

Hunter Syndrome (MPS II): Treatment Overview

Hunter syndrome treatment focuses on reducing glycosaminoglycan accumulation, slowing disease progression, and managing multisystem complications. Enzyme replacement therapy (ERT) with intravenous idursulfase is an established treatment that can improve several somatic manifestations, although conventional idursulfase has limited penetration across the blood-brain barrier. CNS-penetrant ERT, including tividenofusp alfa-eknm, provides an additional therapeutic approach where approved. Supportive management includes respiratory, cardiac, hearing, orthopedic, and rehabilitative care. Hematopoietic stem cell transplantation has been investigated but is not established as standard treatment because controlled evidence in MPS II remains limited.

Key Questions Answered

  • What is the current and projected burden of Hunter syndrome (MPS II) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Hunter syndrome (MPS II) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Hunter syndrome (MPS II) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Hunter syndrome (MPS II) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Hunter syndrome (MPS II) across the 8 major markets?
  • How do major comorbidities and risk factors influence Hunter syndrome (MPS II) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Hunter syndrome (MPS II) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Hunter syndrome (MPS II) landscape across the 8 major markets?
  • Which therapeutic areas linked to Hunter syndrome (MPS II) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Hunter syndrome (MPS II) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Hunter syndrome (MPS II) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Hunter syndrome (MPS II) across the 8 major markets?

Scope of the Hunter Syndrome (MPS II) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Hunter syndrome (MPS II) based on several factors.
  • Hunter Syndrome (MPS II) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Hunter syndrome (MPS II) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Mucopolysaccharidosis Pipeline Analysis

Hunter Syndrome Pipeline Analysis

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us